Overview
I have been engaged in basic and applied cancer research for over 28 years beginning with my post-doctoral fellowship under Arnold Levine at Princeton. Since being appointed to the faculty in the Department of Surgery at Duke, my primary interest has been towards understanding breast and ovarian cancer. I am a charter member of the NCI-Early Detection Research Network (EDRN) and have been an integral scientist in the breast and gynecologic collaborative group for 15 years including leading this group for a 5 year period. I am also a major contributor to the Cancer Genome Atlas and have worked in this context for the past 4 years. My research interests are in the molecular etiology of these diseases and understanding how key genetic events contribute to their onset and progression. My work has been very multi-disciplinary incorporating quantitative, population, genetic, and behavioral approaches. I consider my specialty to be in the area of using human breast and ovarian cancer as the primary and only authentic model system to understand these diseases.
Current Appointments & Affiliations
Recent Publications
Identification of cycling regulatory T cell precursors as conductors of immune escape during breast carcinoma progression.
Journal Article Cancer Cell · April 16, 2026 Immune escape during the ductal carcinoma in situ (DCIS)-to-invasive breast cancer (IBC) transition shapes tumor evolution. Through transcriptomic mapping of the immune landscapes of normal breast, DCIS, and IBC from large patient cohorts, we identified T ... Full text Link to item CiteSpatial proteomics of breast ductal carcinoma in situ reveal distinct regional differences.
Journal Article Sci Rep · March 13, 2026 UNLABELLED: Breast ductal carcinoma in situ is a common non-invasive clinical finding that can progress to invasive breast cancer (IBC). Spatial proteomics can provide an additional dimension to our understanding of this disease and its capacity to progres ... Full text Link to item CitePrognostic Implications of Codon-Specific KRAS Mutations in Localized and Advanced Stages of Pancreatic Cancer.
Journal Article JCO Precis Oncol · February 2026 PURPOSE: Although KRAS mutations represent the primary oncogenic driver in pancreatic ductal adenocarcinoma (PDAC), the association between codon-specific alterations and patient outcomes remains poorly elucidated, largely because of a lack of data sets co ... Full text Link to item CiteRecent Grants
2/3 CTSA K12 Program at Duke University
ResearchMentor · Awarded by National Institutes of Health · 2025 - 2030Duke Research Training Program in Surgical Oncology
Inst. Training Prgm or CMEMentor · Awarded by National Cancer Institute · 2024 - 2029Methylomic Basis of Survival Disparities Among Black and White Women With High-Grade Serous Ovarian Cancer
ResearchPrincipal Investigator · Awarded by H. Lee Moffitt Cancer Center & Research Institute · 2023 - 2027View All Grants